Skip to main navigation Skip to search Skip to main content

Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial

Research output: Contribution to journal › Article › peer-review

Original languageAmerican English
JournalNeuro-oncology
Volume25
StatePublished - Feb 14 2023

Cite this